Gracell Biotechnologies Inc.
GRCLNASDAQHealthcare
$10.25
+$0.01(+0.05%)
Market Cap$197973420
P/E Ratio—
52W High$10.435
52W Low$1.4
Gracell Biotechnologies Inc. (GRCL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GRCL · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | 100.00% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.49B | $0.33B | $0.17B | $0.12B | $0.05B |
| G&A Expenses | $0.14B | $0.14B | $0.05B | $0.03B | $0.01B |
| Total Operating Expenses | $0.62B | $0.46B | $0.21B | $0.15B | $0.06B |
| Operating Income | ($0.62B) | ($0.46B) | ($0.21B) | ($0.15B) | ($0.06B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.02B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.61B) | ($0.45B) | ($0.21B) | ($0.14B) | ($0.06B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.01B) | ($0.01B) | $0.00B |
| Net Income | ($0.61B) | ($0.47B) | ($0.20B) | ($0.13B) | ($0.06B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-44.85 | $-35.40 | $-15.05 | $-33.35 | $-15.35 |
| Wtd Avg Shares | 0.01B | 0.01B | 0.01B | 0.00B | 0.00B |
| EBITDA | ($0.57B) | ($0.39B) | ($0.20B) | ($0.14B) | ($0.06B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more Gracell Biotechnologies Inc. data
About Gracell Biotechnologies Inc. (GRCL) Income Statement
Gracell Biotechnologies Inc. (GRCL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, GRCL reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.61B) — a net profit margin of —.
Frequently asked questions
GRCL · 4 questionsGracell Biotechnologies Inc. (GRCL) reported revenue of $0.00B for 2022, down 100.0% year-over-year.
GRCL revenueGRCL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09